您的位置: 首页 > 农业专利 > 详情页

NOVEL NITRIC OXIDE-ELUTING BIORESORABLE STENTS FOR PERCUTANEOUS CORONARY INTERVENTIONS
专利权人:
Heart Biotech Limited
发明人:
申请号:
EP16164894.4
公开号:
EP3085395B1
申请日:
2016.04.12
申请国别(地区):
EP
年份:
2018
代理人:
摘要:
Bioresorbable stents which elute nitric oxide (NO). The stent is comprised of three main key design elements: a bioresorbable scaffold, a bioresorbable polymeric coating layer(s), and NO-releasing nanoparticles incorporated in the bioresorbable polymeric coating layer, and optionally also in the scaffold. The NO-releasing nanoparticles are made of nontoxic biocompatible and biodegradable materials for example polymers such as chitosan, PEG 400, polyvinyl pyrolidone (PVP), and other materials such as a sugar, glucose, sucrose, alginate, sodium tripolyphosphate and tetramethylorthosilicate. A nitric oxide donor may be loaded onto the nanoparticles, the NO donor may be sodium nitrite. The coating and scaffold may comprise a polymer selected from polyethylene glycol (PEG), polyvinylpyrolidone (PVP), alginate, polyvinyl alcohol (PVA), polyvinyl acetate (PVAc), poly(ethylene-co-vinylacetate) (PEVA), poly(butyl methacrylate) (PBMA), poly(lactic-co-glycolic acid) (PLGA), a chitosan or a chitosan derivative polymer, poly (L-lactide) (PLLA), poly (D-lactide) (PDLA), poly (D,L-lactide) (PDLLA), poly(3-hydroxybutyrate), poly(4-hydroxybutyrate), poly(glycolic acid), polycaprolactone, polyethylene oxide, tyrosine derived polycarbonates, and polyanhydride esters of salicylic acid or a combination of two or more of said polymers. The stent may comprise an additional therapeutic agent such as everolimus, tacrolimus. paclitaxel and sirolimus.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充